AAAAAA

   
Results: 1-10 |
Results: 10
DEVELOPMENT, VALIDATION, AND INTERLABORATORY COMPARISON OF AN HMG-COAREDUCTASE INHIBITION ASSAY FOR QUANTITATION OF ATROVASTATIN IN PLASMAMATRICES
Authors: SHUM YY HUANG NJ WALTER G BLACK A SEKERKE C CHANG T WHITFIELD LR
Citation: Yy. Shum et al., DEVELOPMENT, VALIDATION, AND INTERLABORATORY COMPARISON OF AN HMG-COAREDUCTASE INHIBITION ASSAY FOR QUANTITATION OF ATROVASTATIN IN PLASMAMATRICES, Therapeutic drug monitoring, 20(1), 1998, pp. 41-49
CIMETIDINE DOES NOT ALTER ATORVASTATIN PHARMACOKINETICS OR LDL-CHOLESTEROL REDUCTION
Authors: STERN RH GIBSON DM WHITFIELD LR
Citation: Rh. Stern et al., CIMETIDINE DOES NOT ALTER ATORVASTATIN PHARMACOKINETICS OR LDL-CHOLESTEROL REDUCTION, European Journal of Clinical Pharmacology, 53(6), 1998, pp. 475-478
CLINICALLY RELEVANT SURAMIN DOSING REGIMEN IN MICE WITH NO EFFECTS AGAINST PC-3 PROSTATE XENOGRAFTS
Authors: ROBERTS BJ HOOK KE WHITFIELD LR CARTER CA ELLIOTT WL
Citation: Bj. Roberts et al., CLINICALLY RELEVANT SURAMIN DOSING REGIMEN IN MICE WITH NO EFFECTS AGAINST PC-3 PROSTATE XENOGRAFTS, Oncology Reports, 4(6), 1997, pp. 1361-1366
PHARMACOMETRIC ANALYSIS OF THE EFFECT OF FUROSEMIDE ON SURAMIN PHARMACOKINETICS
Authors: PISCITELLI SC FORREST A LUSH RM RYAN N WHITFIELD LR FIGG WD
Citation: Sc. Piscitelli et al., PHARMACOMETRIC ANALYSIS OF THE EFFECT OF FUROSEMIDE ON SURAMIN PHARMACOKINETICS, Pharmacotherapy, 17(3), 1997, pp. 431-437
FERTILITY AND GENERAL REPRODUCTION STUDIES IN RATS WITH THE HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN
Authors: DOSTAL LA WHITFIELD LR ANDERSON JA
Citation: La. Dostal et al., FERTILITY AND GENERAL REPRODUCTION STUDIES IN RATS WITH THE HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN, Fundamental and applied toxicology, 32(2), 1996, pp. 285-292
TOLERANCE AND PHARMACOKINETICS OF SINGLE-DOSE ATORVASTATIN, A POTENT INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS
Authors: POSVAR EL RADULOVIC LL CILLA DD WHITFIELD LR SEDMAN AJ
Citation: El. Posvar et al., TOLERANCE AND PHARMACOKINETICS OF SINGLE-DOSE ATORVASTATIN, A POTENT INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS, Journal of clinical pharmacology, 36(8), 1996, pp. 728-731
EFFECT OF AGE AND GENDER ON PHARMACOKINETICS OF ATORVASTATIN IN HUMANS
Authors: GIBSON DM BRON NJ RICHENS A HOUNSLOW NJ SEDMAN AJ WHITFIELD LR
Citation: Dm. Gibson et al., EFFECT OF AGE AND GENDER ON PHARMACOKINETICS OF ATORVASTATIN IN HUMANS, Journal of clinical pharmacology, 36(3), 1996, pp. 242-246
MULTIPLE-DOSE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF ATORVASTATIN, AN INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS
Authors: CILLA DD WHITFIELD LR GIBSON DM SEDMAN AJ POSVAR EL
Citation: Dd. Cilla et al., MULTIPLE-DOSE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF ATORVASTATIN, AN INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS, Clinical pharmacology and therapeutics, 60(6), 1996, pp. 687-695
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR CI-980, A NOVEL 1-DEAZA-7,8-DIHYDROPTERIDINE ANTICANCER AGENT, IN HUMAN PLASMA AND URINE
Authors: BULLEN WW WHITFIELD LR WALTER GA BRODFUEHRER JI
Citation: Ww. Bullen et al., HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR CI-980, A NOVEL 1-DEAZA-7,8-DIHYDROPTERIDINE ANTICANCER AGENT, IN HUMAN PLASMA AND URINE, Journal of chromatography B. Biomedical applications, 668(1), 1995, pp. 141-151
EFFECT OF FOOD ON THE BIOAVAILABILITY OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR
Authors: RADULOVIC LL CILLA DD POSVAR EL SEDMAN AJ WHITFIELD LR
Citation: Ll. Radulovic et al., EFFECT OF FOOD ON THE BIOAVAILABILITY OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, Journal of clinical pharmacology, 35(10), 1995, pp. 990-994
Risultati: 1-10 |